Clinical trial
A Multicenter, Open Label, Single-Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)
NCT03981536 is registered in ClinicalTrials.gov with AL-S Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Open Label, Single-Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)
- Lead sponsor
- AL-S Pharma
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- October 10, 2019
- Completion date
- November 2, 2020
- Enrollment
- 18 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.